BRCA1 is considered to be a differential modulator of tumor response to cisplatin and taxanes [5-7], and BRCA1 levels are reportedly associated with chemosensitivity to cisplatin [8] and taxanes [9,10]. Here, BRCA1 is linked to neoplasm.